“So, what we’ve done is develop a technique, using the NAM technology, to expand those stem cells, so we can make 50 to 100-fold more stem cells, with higher reliability, and manufacture those cells for patients in need of a bone marrow transplant”
Gene and cell therapies, while still requiring research regarding their safety and efficacy for patients, offer promising results for treatment of hematological malignancies. Omidubicel (NiCord), an investigational agent manufactured by Gamida Cell, is currently being studied as an allogeneic hematopoietic stem cell transplant solution in treating diseases of the blood.
According to the phase 3 study (NCT02730299), the use of omidubicel resulted in a significantly improved median time to neutrophil engraftment in comparison to standard umbilical blood transplantation. The trial and it’s encouraging results in patients with high-risk hematologic malignancies were presented earlier this year at the Virtual 47th Annual Meeting of the European Society for Blood and Marrow transplantation.
Julian Adams, PhD, chief executive officer, Gamida Cell, sat down with GeneTherapyLive to explain a bit about the company and its approach to cell therapy as well the possibility of omidubicel as an alternative to bone marrow transplant in leukemias and lymphomas.
Sanz GF, Stiff PJ, Cutler CS, et al. Results of a phase III randomized, multicenter study comparing omidubicel with standard umbilical cord blood transplantation (UCBT) in patients with high-risk hematologic malignancies following myeloablation. Presented at: 47th Annual Meeting of the EBMT; March 14-17, 2021; Virtual. Abstract GS2-7.
This was originally published on GeneTherapyLive as “Improving Bone Marrow Transplant with Omidubicel”